TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00018057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training
Description: The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Bias Modification Training
Description: The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Randomized assignment.
Study: NCT02907398

Intervention type: DEVICE
Intervention: Inspire therapy

Intervention type: OTHER
Intervention: No intervention
Study: NCT04408755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study: NCT03727633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin and Lipiodol
Description: Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
Study: NCT02868021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strength testing
Description: Test the strength of subject's lower extremity muscles on the dynamometer system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Strength testing
Description: Test the strength of subject's lower extremity muscles on the dynamometer system

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Description: The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
Study: NCT04666636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
Study: NCT04417998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-AV1451
Description: A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Siemens E7 Reconstruction Tool
Description: Software to correct for motion
Study: NCT04824079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keynatinib
Description: The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
Study: NCT02868021

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Short Physical Performance Battery (SPPB)
Description: The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six-minute walk (SMW)
Description: Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Six-minute walk (SMW)
Description: Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numerical pain scale
Description: Measure pain using an 11-point numerical pain scale.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Numerical pain scale
Description: Measure pain using an 11-point numerical pain scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessed function
Description: Using the Late Life Function and Disability Instrument.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-assessed function
Description: Using the Late Life Function and Disability Instrument.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsies
Description: During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle biopsies
Description: During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination of 1 Repetition Maximum (1-RM)
Description: Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction exercise
Description: Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Borg CR10 scale
Description: Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
Study: NCT01476267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: Single oral radiolabeled dose
Study: NCT00642005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fisher and Paykel Humidifier (MR860)
Description: Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard insufflation
Description: No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
Study: NCT04382716

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; observation only
Study: NCT03646747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Additional imaging using MRI scan
Study: NCT02213380

Intervention type: PROCEDURE
Group type: OTHER
Intervention: method of anesthesia
Description: General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA

Intervention type: PROCEDURE
Group type: OTHER
Intervention: method of anesthesia
Description: General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA
Study: NCT00905632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 middle dose +SOC
Description: BI 207127 middle dose tid + SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 high dose+SOC
Description: BI 207127 high dose tid +SOC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: Placebo tid +SOC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 low dose + SOC
Description: BI 207127 low dose tid + SOC
Study: NCT04032795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium barbarum polysaccharide
Description: Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
Study: NCT03331263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 2% CHG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 2% CHG
Study: NCT03671655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Description: Drug eluting stent which are nitinol stent coated with Paclitaxel drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
Study: NCT04127877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICAS
Description: Electric regional bio impedance device
Study: NCT03937544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T CELLS
Description: CD19 CAR-T cells will be administered after completion of the chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).
Study: NCT00594893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Incision Approach
Description: Mini Incision Approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 Incision Approach
Description: 2 Incision Approach
Study: NCT02542397

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Testing
Description: Pharmacogenomic test results to guide drug/dose modifications
Study: NCT02726789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca
Description: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: local generic entecavir
Study: NCT05868681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delos instrument (computerized balance board)
Description: Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction.
Study: NCT01589419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: see arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: see arm description

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: see arm description
Study: NCT03106883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective training
Description: 3 sessions of active training using affective faces to modify the negative attention bias in depression

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: 3 sessions of sham attention training using non-affective stimuli
Study: NCT02554045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
Study: NCT00305669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunological diagnostic method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study: NCT04584840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal.
Study: NCT03643510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
Study: NCT02259400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NSIPPV
Description: In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)\< 0.3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP
Description: In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 \< 0.3.
Study: NCT03570775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleeping bag phototherapy
Description: This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phototherapy
Description: This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
Study: NCT03735407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan procedure
Description: The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,
Study: NCT00697593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
Description: Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
Study: NCT01158742

Intervention type: OTHER
Intervention: Glomerular Filtration Rate with Iothalamate
Description: used to determine kidney function

Intervention type: OTHER
Intervention: Glomerular Filtration Rate with Iothalamate
Description: used to determine kidney function

Intervention type: OTHER
Intervention: Glomerular Filtration Rate with Iohexol
Description: used to determine kidney function
Study: NCT00812175

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Systemic oral therapy according to product information
Study: NCT01867515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic distortion of speech

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic distortion of speech

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic distortion of speech
Study: NCT03419117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: An ESP block will be performed prior to surgery for postoperative pain control

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sham ESP block will be performed before surgery in the placebo group
Study: NCT00926757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir prophylaxis
Description: Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic entecavir
Description: Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
Study: NCT01214668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: 40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met.
Study: NCT01637714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotics
Description: * B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water
Study: NCT03489252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit Charge 3
Study: NCT01308034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring.